Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
University of Heidelberg Medical Center
Amgen
Oncternal Therapeutics, Inc
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals